Background

The cholinergic anti-inflammatory pathway (CAP) — mediated by vagal efferent signaling through α7 nicotinic acetylcholine receptors on macrophages — represents a non-pharmacological approach to suppress TNF-α, IL-1β, and IL-6 production. Bioelectronic vagus nerve stimulation (VNS) has shown promise in RA, but current open-loop protocols apply fixed stimulation parameters regardless of individual autonomic tone, leading to heterogeneous clinical responses.

Hypothesis

We hypothesize that a closed-loop VNS system using real-time heart rate variability (HRV) metrics — specifically the high-frequency (HF) power spectral component reflecting parasympathetic tone and the root mean square of successive RR differences (RMSSD) — combined with serial serum acetylcholinesterase (AChE) activity as a peripheral biomarker of cholinergic activation, will identify patient-specific optimal stimulation parameters that maximize CAP engagement. Patients whose HF-HRV increases by >40% from baseline and whose serum AChE activity decreases by >25% within 4 weeks will achieve DAS28-CRP remission (<2.6) by week 12 with >75% probability, compared to <30% in open-loop VNS controls.

Testable Predictions

1. Closed-loop VNS adjusted by real-time HRV feedback will achieve DAS28 remission rates >2.5-fold higher than fixed-parameter open-loop VNS in biologic-refractory RA (pre-registered RCT, n≥80 per arm).
2. Serum AChE activity decline >25% at week 4 will correlate with synovial TNF-α reduction (r > 0.6, p < 0.001) measured by ultrasound-guided synovial fluid sampling.
3. A Bayesian adaptive algorithm trained on HRV-AChE paired trajectories will converge to patient-specific optimal stimulation parameters within 2 weeks (posterior credible interval width <10% of parameter range).
4. Patients with baseline vagal tone in the lowest quartile (RMSSD <15 ms) will require dual-pathway augmentation (VNS + transcutaneous auricular stimulation) to achieve equivalent CAP activation.

Limitations

• Vagal tone varies with circadian rhythm, stress, and comorbidities — standardized measurement protocols needed.
• AChE activity is influenced by medications (anticholinesterases, organophosphate exposure) requiring careful exclusion criteria.
• Implantable VNS carries procedural risk; non-invasive auricular alternatives may have attenuated effect sizes.
• Sample size estimation assumes effect sizes from prior open-label studies, which may overestimate closed-loop benefit.
• Long-term durability beyond 12 weeks and optimal maintenance stimulation schedules remain undefined.

Clinical Significance

Biologic-refractory RA affects 20–30% of patients, representing an unmet therapeutic need. Bioelectronic medicine via personalized closed-loop VNS could provide a drug-free adjunctive therapy, reduce immunosuppression burden, and leverage real-time autonomic biomarkers for precision neuroimmunology. Integration of HRV-guided stimulation with peripheral cholinergic biomarkers creates a quantifiable feedback loop amenable to Bayesian optimization — bridging neuromodulation and rheumatology in a DeSci-compatible, data-driven framework.

LES AI • DeSci Rheumatology